UDCA has, therefore, been evaluated for the treatment of patients with PSC. Trials of UDCA at low doses (10–15 mg/kg per day and 17–20 mg/kg per day) have yielded inconclusive results in ...

The ground-breaking study, led by researchers at the University of Sheffield in partnership with Sheffield Teaching Hospitals NHS Foundation Trust, is assessing the safety and tolerability of the ...

Advanz Pharma’s liver disease drug Ocaliva (obeticholic acid) will no longer be available in Europe after the General Court of the European Union upheld a decision by the European Commission (EC ...

Discover all the brand names or Trade names of generic drug called Ursodeoxycholic Acid. This serves as a crucial reference for healthcare professionals, patients, caregivers, and anyone looking ...

GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive. We believe there ...

Analysts have suggested that the US market for drugs to treat UDCA-refractory PBC could be worth $1.5 billion or more per year. Gilead acquired Livdelzi – an oral PPAR delta agonist – as the ...

The trials identified no serious adverse effects, and patients tolerated a daily dosage of 1500 mg for 24 weeks.